Angle Interleaved Projection Reconstruction with K-Space Weighted
Image Reconstruction for Dynamic Contrast MRI of Cancer Therapy Response 

Note: Funded by the PA Department of Health and carried out by ACRIN PA Network institutions

Protocol Documents

Protocol-ACRIN 4002 Amendment 3, 6.29.09 [PDF]

SOC-ACRIN PA 4002 Amendment 3, 6.30.09 [PDF]

Informed Consent-ACRIN PA 4002 [DOC]

Principal Investigator:  Mark Rosen, MD, PhD

Status:  Closed To Accrual

Main Objective: The objectives of this study are to test the feasibility and reliability of implementing a novel MRI acquisition scheme for rapid dynamic contrast enhanced MRI (DCE-MRI) across multiple imaging platforms. The novel technique, angle-interleaved back projection acquisition, will be developed across imaging platforms at up to four institutions in Pennsylvania. It will then be tested on a phantom system and on healthy volunteers.  If successful, a clinical trial of DCE-MRI will be conducted to evaluate vascular changes induced by chemotherapy containing the anti-angiogenic agent, bevacizumab, in persons with metastatic colorectal cancer.

Participants: All patients with colorectal cancer metastatic to the liver who will receive FOLFOX chemotherapy with bevacizumab are eligible for this study. In addition, each patient must have a measurable viable liver tumor as described in the Imaging Inclusion Criteria section of the protocol.

Study Design Summary: A total of 60 participants will be enrolled into the study over one year. Projection reconstruction DCE-MRI (DCE-MRI) will be used to determine reproducibility of the methodology for determining kinetic parameters of tumor gadolinium entry (e.g. Ktrans) and to gauge the relationship between bevacizumab-induced changes in tumor Ktrans and clinical parameters of tumor response.